Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

The Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) is a disorder of water balance characterized by the excessive and unsuppressed release of antidiuretic hormone (ADH, also known as arginine vasopressin, AVP) from the posterior pituitary or from ectopic sources, in the absence of an osmotic or hemodynamic stimulus. This leads to impaired renal water excretion, resulting in dilutional hyponatremia, hypoosmolality, and euvolemia (normal or slightly expanded extracellular fluid volume). In veterinary medicine, SIADH is a rare but clinically significant cause of hyponatremia, often associated with intracranial disease, pulmonary disorders, or certain neoplasms. The condition is classified as a euvolemic hyponatremia, distinguishing it from hypovolemic (e.g., gastrointestinal loss) and hypervolemic (e.g., congestive heart failure, cirrhosis) causes. The clinical severity ranges from asymptomatic mild hyponatremia to life-threatening neurological signs due to cerebral edema. Accurate diagnosis requires documentation of hypotonic hyponatremia, inappropriately concentrated urine, and clinical euvolemia, while excluding other causes such as hypothyroidism, hypoadrenocorticism, and diuretic use.

The etiology of SIADH in dogs and cats can be categorized into four main groups: (1) Malignant neoplasms producing ectopic ADH, (2) Pulmonary disorders, (3) Central nervous system (CNS) disorders, and (4) Drug-induced causes. In veterinary patients, the most commonly reported causes include intracranial disease (e.g., hydrocephalus, traumatic brain injury, encephalitis, brain tumors), pulmonary disease (e.g., pneumonia, lung tumors, positive pressure ventilation), and certain neoplasms (e.g., lymphoma, pulmonary carcinoma, pancreatic adenocarcinoma). Ectopic ADH production has been documented in various tumors, including small cell lung carcinoma (rare in animals), pancreatic islet cell tumors, and thymomas. Drug-induced SIADH can occur with medications such as vincristine, cyclophosphamide, opiates, and selective serotonin reuptake inhibitors (SSRIs), though these are less commonly reported in veterinary medicine. Additionally, idiopathic cases have been described. The underlying mechanism involves either autonomous ADH secretion from a tumor or non-osmotic stimulation of ADH release from the posterior pituitary due to CNS or pulmonary pathology. In some cases, the cause remains undetermined despite extensive diagnostic evaluation.

SIADH is a rare diagnosis in veterinary medicine, with limited epidemiological data. It has been reported in both dogs and cats, but the exact incidence is unknown. There is no apparent breed or sex predisposition, although the condition may be more commonly recognized in young to middle-aged animals due to the higher prevalence of congenital or traumatic CNS disorders in this population. In dogs, SIADH has been associated with breeds predisposed to hydrocephalus, such as Chihuahuas, Yorkshire Terriers, and Maltese, but this is not a consistent finding. In cats, SIADH has been reported in cases of intracranial disease, particularly following traumatic brain injury or with intracranial neoplasia. The condition is likely underdiagnosed because mild hyponatremia may be asymptomatic and not investigated. Geographic and seasonal variations are not well-documented, but the incidence may increase with the prevalence of underlying etiologies, such as head trauma or infectious encephalitis.

The pathophysiology of SIADH centers on the inappropriate secretion of ADH, leading to increased water reabsorption in the renal collecting ducts via aquaporin-2 channels. Normally, ADH is released in response to increased plasma osmolality (detected by osmoreceptors in the hypothalamus) or decreased effective circulating volume (detected by baroreceptors in the carotid sinus and aortic arch). In SIADH, ADH is secreted despite hypotonicity and euvolemia, causing the kidneys to retain water excessively. This results in expansion of the extracellular fluid volume, but because the retained water is distributed across total body water, the patient remains clinically euvolemic (no edema). The expanded volume leads to increased atrial natriuretic peptide (ANP) release and suppression of the renin-angiotensin-aldosterone system, promoting natriuresis and maintaining a new steady state with hyponatremia. The hallmark is a urine osmolality that is inappropriately high (greater than 100 mOsm/kg) relative to plasma osmolality, and urine sodium concentration is typically > 40 mmol/L due to natriuresis. The resulting hypotonic hyponatremia causes water to move into cells, particularly neurons, leading to cerebral edema and neurological signs. The severity of clinical signs correlates with the degree and rapidity of the fall in plasma sodium concentration. Chronic hyponatremia allows brain cells to adapt by losing intracellular solutes (osmolytes), reducing the risk of severe cerebral edema, but rapid correction can lead to osmotic demyelination syndrome (central pontine myelinolysis).

Predisposing factors for SIADH include any condition that can trigger non-osmotic ADH release or ectopic ADH production. Intrinsic factors include genetic predisposition to CNS disorders (e.g., hydrocephalus in toy breeds), age (young animals with congenital anomalies, older animals with neoplasia), and concurrent endocrine or metabolic diseases that may complicate fluid balance. Extrinsic factors include traumatic brain injury, intracranial surgery, pulmonary infections (e.g., bacterial or viral pneumonia), mechanical ventilation, and certain medications (e.g., vincristine, cyclophosphamide, opiates, SSRIs). Additionally, stress, pain, and anesthesia can stimulate ADH release, potentially exacerbating the condition. In hospitalized patients, fluid therapy with hypotonic solutions can worsen hyponatremia if SIADH is unrecognized. The presence of underlying neoplasia, particularly thoracic or abdominal tumors, should be considered a risk factor for ectopic ADH production.

Clinical signs of SIADH are primarily neurological and relate to the degree and rapidity of hyponatremia. In mild cases (plasma sodium > 130 mmol/L), animals may be asymptomatic or show subtle signs such as lethargy, anorexia, and mild weakness. As sodium falls below 125 mmol/L, signs progress to disorientation, ataxia, weakness, and muscle fasciculations. Severe hyponatremia (< 120 mmol/L) can lead to seizures, stupor, coma, and death due to cerebral edema. The onset of signs is more acute with rapid drops in sodium. Physical examination typically reveals euvolemia (normal skin turgor, moist mucous membranes, no edema), but may also show signs of the underlying disease (e.g., neurological deficits from head trauma, respiratory signs from pneumonia). In chronic cases, animals may present with chronic lethargy and inappetence without overt neurological signs. It is important to note that clinical signs are non-specific and can be mistaken for other causes of neurological dysfunction.

Differential diagnoses for hyponatremia in dogs and cats include: (1) Hypoadrenocorticism (Addison's disease) – typically presents with hyperkalemia, hypovolemia, and lack of stress leukogram; ACTH stimulation test is diagnostic. (2) Hypothyroidism – can cause hyponatremia due to decreased cardiac output and reduced glomerular filtration rate; thyroid hormone levels are low. (3) Gastrointestinal losses (vomiting, diarrhea) – leading to hypovolemic hyponatremia with prerenal azotemia and concentrated urine. (4) Renal disease – chronic kidney disease can cause hyponatremia due to impaired concentrating ability and sodium loss; urine specific gravity is isosthenuric. (5) Congestive heart failure – hypervolemic hyponatremia with ascites, edema, and pleural effusion. (6) Hepatic cirrhosis – hypervolemic hyponatremia with ascites and hypoalbuminemia. (7) Psychogenic polydipsia – primary polydipsia leads to dilute urine (USG < 1.008) and low urine osmolality. (8) Diuretic use (e.g., furosemide) – can cause hypovolemic hyponatremia with elevated urine sodium. (9) Pseudohyponatremia – due to hyperlipidemia or hyperproteinemia, but plasma osmolality is normal. (10) Cerebral salt wasting – occurs with CNS disease, but is characterized by hypovolemia and excessive natriuresis, whereas SIADH is euvolemic.

The diagnostic approach to SIADH involves a stepwise algorithm: (1) Confirm true hyponatremia by measuring plasma osmolality (calculated as 2[Na+] + glucose/18 + BUN/2.8) – SIADH is associated with hypoosmolality (< 280 mOsm/kg). (2) Assess volume status – SIADH is euvolemic; clinical evaluation (skin turgor, mucous membranes, heart rate, blood pressure) and measurement of central venous pressure if needed. (3) Measure urine osmolality – in SIADH, urine osmolality is inappropriately high (> 100 mOsm/kg, often > 300 mOsm/kg) despite plasma hypoosmolality. (4) Measure urine sodium concentration – typically > 40 mmol/L in SIADH due to natriuresis, but this can be variable. (5) Exclude other causes: rule out hypoadrenocorticism (ACTH stimulation test), hypothyroidism (total T4, free T4, TSH), renal disease (creatinine, SDMA, urinalysis), and diuretic use. (6) Evaluate for underlying etiologies: thoracic radiographs (pulmonary masses, pneumonia), abdominal ultrasound (neoplasia), brain MRI (intracranial lesions), and infectious disease testing (e.g., toxoplasmosis, distemper) if indicated. (7) If no underlying cause is found, consider idiopathic SIADH. (8) In challenging cases, a water loading test can be performed, but this is rarely done in clinical practice due to risks. The diagnosis is confirmed by the presence of hypotonic hyponatremia, euvolemia, inappropriately concentrated urine, and elevated urine sodium, with normal adrenal and thyroid function.

Laboratory findings in SIADH include: (1) Serum biochemistry: hyponatremia (plasma sodium < 135 mmol/L), hypoosmolality (plasma osmolality < 280 mOsm/kg), and often mild hypochloremia. Potassium is typically normal or slightly low. BUN and creatinine are usually within normal limits, reflecting euvolemia. (2) Urinalysis: urine specific gravity is inappropriately high (> 1.030 in dogs, > 1.035 in cats) despite hyponatremia; urine osmolality > 100 mOsm/kg; urine sodium concentration > 40 mmol/L. (3) Hematology: no specific changes, but may reflect underlying disease (e.g., leukocytosis with infection). (4) Endocrine testing: normal cortisol response to ACTH stimulation (to rule out hypoadrenocorticism), normal thyroid hormone levels (to rule out hypothyroidism). (5) Blood gas analysis: may show mild metabolic acidosis or alkalosis depending on underlying disease. (6) Biomarkers: not specific for SIADH, but may be used to assess underlying conditions (e.g., NT-proBNP for cardiac disease, SDMA for renal function). (7) Serum osmolality can be measured directly or calculated; calculated osmolality is often used. (8) In cases of ectopic ADH production, ADH levels may be measured, but this assay is not widely available and is rarely necessary for diagnosis.

Imaging is essential to identify underlying causes of SIADH. Thoracic radiographs should be performed to evaluate for pulmonary masses, pneumonia, or other thoracic pathology. Abdominal ultrasound may reveal neoplasia (e.g., pancreatic mass, adrenal mass) or other abnormalities. For suspected intracranial disease, magnetic resonance imaging (MRI) of the brain is the modality of choice, as it can detect hydrocephalus, brain tumors, inflammation, or traumatic lesions. Computed tomography (CT) may be used if MRI is unavailable, particularly for trauma or calcified lesions. In cases of suspected pituitary or hypothalamic lesions, contrast-enhanced imaging is recommended. Echocardiography may be indicated if cardiac disease is suspected as a differential. Imaging findings are not specific for SIADH but are crucial for identifying the underlying etiology and guiding treatment.

Cytology and histopathology are primarily used to diagnose underlying neoplasms or inflammatory conditions that may cause SIADH. Fine needle aspirates of thoracic or abdominal masses can be evaluated for neoplastic cells (e.g., lymphoma, carcinoma). Histopathology of biopsy samples from tumors may reveal neuroendocrine features, and immunohistochemistry for ADH or chromogranin A can support ectopic ADH production. In cases of CNS disease, cerebrospinal fluid analysis may show inflammation or neoplastic cells. However, these findings are not specific to SIADH but are important for identifying the cause. In idiopathic SIADH, no specific cytological or histopathological abnormalities are expected.

The treatment of SIADH involves two main goals: (1) Correction of hyponatremia, and (2) Management of the underlying cause. In asymptomatic or mildly symptomatic patients, water restriction is the first-line therapy. Fluid intake (oral and intravenous) should be limited to insensible losses (approximately 20-30 ml/kg/day) plus urine output. In hospitalized patients, isotonic saline (0.9% NaCl) may be used cautiously, but it can worsen hyponatremia if the urine is highly concentrated, as the sodium may be excreted while water is retained. For moderate to severe hyponatremia with neurological signs, hypertonic saline (3% NaCl) is indicated, but must be administered carefully to avoid rapid correction. The recommended rate of correction is 0.5-1 mEq/L/hour, with a maximum of 8-12 mEq/L in 24 hours, to prevent osmotic demyelination. In chronic hyponatremia, even slower correction is advised. Pharmacological options include demeclocycline (a tetracycline that induces nephrogenic diabetes insipidus) at a dose of 15-25 mg/kg PO q8h, but it is not commonly used in veterinary medicine due to availability and side effects. Vasopressin receptor antagonists (vaptans) such as tolvaptan have been used experimentally in dogs, but are not approved for veterinary use. Conivaptan has been used in dogs at 0.5-1 mg/kg IV, but experience is limited. Treatment of the underlying cause is essential; for example, surgical resection of a tumor, antibiotics for pneumonia, or management of intracranial disease. In cases of drug-induced SIADH, the offending drug should be discontinued. Supportive care includes monitoring of neurological status, electrolyte levels, and fluid balance.

The prognosis for SIADH depends on the underlying cause and the severity of hyponatremia. In cases where the underlying cause is reversible (e.g., drug-induced, pneumonia), the prognosis is good with appropriate treatment. In cases associated with neoplasia or severe intracranial disease, the prognosis is guarded to poor, depending on the tumor type and stage. The prognosis is also influenced by the rapidity of diagnosis and correction of hyponatremia. If hyponatremia is corrected too rapidly, osmotic demyelination can occur, leading to permanent neurological deficits and a poor prognosis. Mortality rates are not well-defined, but severe hyponatremia (sodium < 120 mmol/L) is associated with a high risk of death if untreated. In chronic, well-managed cases, animals can have a good quality of life for months to years, especially if the underlying cause is controlled.

Follow-up for SIADH involves regular monitoring of serum sodium, plasma osmolality, and clinical signs. Initially, sodium should be checked every 4-6 hours during correction, then daily until stable. Once stable, weekly or monthly monitoring may be appropriate depending on the underlying cause. If the patient is on water restriction, body weight and urine output should be monitored. Repeat imaging (e.g., thoracic radiographs, abdominal ultrasound, brain MRI) may be indicated to assess response to treatment of the underlying disease. If the patient is on demeclocycline or vaptans, renal function and liver enzymes should be monitored periodically. Long-term management may require continued water restriction and periodic sodium checks. Owners should be educated on signs of hyponatremia (lethargy, weakness, seizures) and the importance of avoiding hypotonic fluids. In cases of idiopathic SIADH, lifelong management may be necessary.

Pearls: (1) Always consider SIADH in any patient with euvolemic hyponatremia and concentrated urine. (2) Measure urine osmolality and urine sodium to confirm the diagnosis. (3) Rule out hypoadrenocorticism before treating for SIADH, as it is a common and life-threatening differential. (4) In patients with neurological signs, use hypertonic saline but correct sodium slowly to avoid osmotic demyelination. (5) Look for underlying causes, especially thoracic masses and intracranial disease. Pitfalls: (1) Administering isotonic saline to a SIADH patient can worsen hyponatremia because the water is retained and sodium is excreted. (2) Rapid correction of chronic hyponatremia can cause central pontine myelinolysis, leading to severe neurological deficits. (3) Failing to recognize that urine sodium may be low if the patient is on a low-sodium diet or has been vomiting. (4) Overlooking drug-induced SIADH in patients receiving chemotherapy or opioids. (5) Assuming that hyponatremia is due to hypoadrenocorticism without performing an ACTH stimulation test.

Current drug protocols for SIADH are primarily supportive and aimed at correcting hyponatremia and managing underlying causes. (1) Hypertonic saline (3% NaCl): For severe hyponatremia with neurological signs, administer 3% NaCl at a rate of 1-2 ml/kg over 15-30 minutes, then reassess. The goal is to increase serum sodium by 0.5-1 mEq/L/hour, not exceeding 8-12 mEq/L in 24 hours. (2) Isotonic saline (0.9% NaCl): Use cautiously, only if urine osmolality is low (< 200 mOsm/kg), otherwise it may worsen hyponatremia. (3) Demeclocycline: 15-25 mg/kg PO q8h, but may take 3-5 days to work; monitor renal function. (4) Vaptans (e.g., tolvaptan): Not approved for veterinary use, but experimental doses in dogs: tolvaptan 0.5-1 mg/kg PO q24h; conivaptan 0.5-1 mg/kg IV over 30 minutes, then 0.5-1 mg/kg/day CRI. (5) Furosemide: May be used in combination with hypertonic saline to enhance free water excretion, but is not first-line. (6) Treatment of underlying cause: e.g., antibiotics for pneumonia, surgical resection of tumors, glucocorticoids for inflammatory CNS disease. (7) Water restriction: Limit total fluid intake to 20-30 ml/kg/day, adjusting for urine output and insensible losses. (8) In cases of drug-induced SIADH, discontinue the offending drug. All dosages should be adjusted based on renal and hepatic function, and patients should be monitored closely for electrolyte imbalances.

Evidence-based literature on SIADH in veterinary medicine is limited to case reports and small case series. A review by DiBartola (2012) in 'Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice' provides a comprehensive overview of hyponatremia and SIADH. Case reports have documented SIADH in dogs with hydrocephalus, traumatic brain injury, and pulmonary carcinoma, and in cats with intracranial disease. A study by Rishniw and colleagues (2010) evaluated the use of tolvaptan in healthy dogs, showing its efficacy in increasing free water clearance, but clinical use remains experimental. The ACVIM consensus statement on hyponatremia (2013) provides guidelines for diagnosis and treatment, emphasizing the importance of slow correction to prevent osmotic demyelination. In human medicine, SIADH is well-characterized, and veterinary recommendations are often extrapolated from human guidelines. There is a lack of large-scale veterinary studies, and treatment protocols are based on expert opinion and anecdotal evidence. Future research should focus on the prevalence of SIADH in veterinary patients and the safety and efficacy of vaptans.